Behavioral Effects of Drugs (Inpatient): 43 (Opioids, Cocaine, n-Acetylcysteine)

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

EARLY_PHASE1

Total Enrollment

24 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-12-15

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The overarching hypotheses of this protocol are that (1) persistent brain glutamate changes induced by chronic opioid use will exacerbate use of cocaine during opioid physical dependence and withdrawal and (2) n-acetylcysteine (NAC) will ameliorate glutamatergic dysregulation, and thus will reduce both opioid and cocaine demand. These hypotheses will be tested with two specific aims.

Specific Aim 1. Determine the reinforcing effects of cocaine in individuals with comorbid opioid and cocaine use disorder with physiological dependence on opioids during NAC maintenance. All subjects will be maintained on oral hydromorphone. They will also be randomly assigned to receive placebo or oral NAC (2.4 g/day), stratified by sex. After dose stabilization, experimental sessions will be conducted in which subjects complete hypothetical cocaine purchase tasks during opioid maintenance and opioid withdrawal. The hypotheses are: 1) cocaine purchasing will be greater during opioid withdrawal and 2) NAC maintenance will attenuate cocaine purchasing across opioid maintenance and withdrawal periods.

Specific Aim 2. Evaluate glutamate functionality during periods of opioid maintenance and withdrawal in individuals with comorbid opioid and cocaine use disorder and physiological dependence on opioids during NAC maintenance. Subjects will undergo magnetic resonance spectroscopy to evaluate brain glutamate changes as a function of opioid maintenance/withdrawal state and NAC maintenance. The hypotheses are: 1) glutamate levels will be elevated during opioid withdrawal and 2) NAC maintenance will ameliorate elevated glutamate levels.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

n-Acetylcysteine and Cocaine

NCT02141620

Cocaine Abuse Cocaine Dependence

COMPLETED EARLY_PHASE1

N-Acetyl Cysteine Plus Naltrexone in Methamphetamine Dependence

NCT00332605

Methamphetamine Dependence

COMPLETED PHASE2

Brain Dopaminergic Signaling in Opioid Use Disorders

NCT03190954

Normal Physiology Opioid Use Disorders

COMPLETED EARLY_PHASE1

Naltrexone in Two Models of Psychosocial Treatments for Cocaine and Alcohol Dependence

NCT00167232

Cocaine Dependence Alcoholism

COMPLETED PHASE3

[11C]NOP-1A and Cocaine Use Disorders

NCT03348384

Cocaine Use Disorder

COMPLETED EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cocaine Use Disorder Opioid Use Disorder Stimulant Use Disorder

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

This study will use a double-blind, placebo-controlled design with all subjects receiving all hydromorphone (i.e., hydromorphone dose is a within subject factors). Half of the subjects will receive placebo and half of the subjects will receive 2.4mg/day NAC.

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

n-Acetylcysteine

Subjects will receive 0.6 g oral n-acetylcysteine 4 times per day.

Group Type EXPERIMENTAL

n-acetylcysteine

Intervention Type DRUG

Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.

Hydromorphone

Intervention Type DRUG

Subjects will receive up to 192 mg oral hydromorphone daily.

Placebo hydromorphone

Intervention Type DRUG

Prior to some experimental sessions, subjects will receive placebo hydromorphone

Placebo

Subjects will receive oral placebo 4 times per day.

Group Type PLACEBO_COMPARATOR

Hydromorphone

Intervention Type DRUG

Subjects will receive up to 192 mg oral hydromorphone daily.

Placebo n-acetylcystine

Intervention Type DRUG

Subjects will be randomized to receive placebo n-acetylcysteine daily.

Placebo hydromorphone

Intervention Type DRUG

Prior to some experimental sessions, subjects will receive placebo hydromorphone

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

n-acetylcysteine

Subjects will be randomized to receive 2.4 oral n-acetylcysteine daily.

Intervention Type DRUG

Hydromorphone

Subjects will receive up to 192 mg oral hydromorphone daily.

Intervention Type DRUG

Placebo n-acetylcystine

Subjects will be randomized to receive placebo n-acetylcysteine daily.

Intervention Type DRUG

Placebo hydromorphone

Prior to some experimental sessions, subjects will receive placebo hydromorphone

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Between the ages of 18 and 55 years,
2. Report recent use of opioids and cocaine and must not be seeking treatment for their drug use,
3. Be physically dependent on short-acting opioids,
4. Meet Diagnostic and Statistical Manual (DSM)-5 diagnostic criteria for current opioid use disorder (OUD) and current or past cocaine use disorder (CUD) and have either a urine sample positive for recent opioid use during each visit or if opioid negative, displaying frank withdrawal during screening
5. Other than the diagnosis for opioid and cocaine use disorder at the time of the screening, subjects must be healthy,
6. Laboratory chemistries (e.g., blood chemistry screen, complete blood count, urinalysis) and electrocardiogram (ECG) results must be normal or within normal range and any abnormal results must be considered as not clinically significant by the study physicians,
7. No contraindications to magnetic resonance imagining (MRI; e.g., metallic objects in their body, BMI \> or = 40, claustrophobia) will be considered ineligible,
8. Female subjects must be using an effective form of birth control (e.g., birth control pills, surgical sterilization, intrauterine device, barrier method, condoms with spermicide, cervical cap with a spermicide or abstinence) to participate and must not be pregnant,
9. All study subjects will be judged by the medical staff to be psychiatrically and physically healthy.

Exclusion Criteria

1. Any potential subject with a history of serious physical disease, current physical disease (e.g., impaired cardiovascular functioning, histories of seizure, head trauma, diabetes, asthma, or central nervous system \[CNS\] tumors) or current or past histories of serious psychiatric disorder (e.g., schizophrenia) that would limit compliance in the study, other than substance use disorder, will be excluded from research participation,
2. Potential subjects that meet diagnostic criteria for moderate - severe substance use disorder for substances other than opioids, stimulants, cannabis, or nicotine at the time of the interview will not be eligible for study participation,
3. Subjects who report a positive first-degree family history of schizophrenia, serious cardiovascular disease, or seizure disorders will also be excluded from research participation.
4. Subjects with contraindications to hydromorphone or n-acetylcysteine will not be eligible.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes